Post by Alexion Pharmaceuticals, Inc.

As the 63rd European Renal Association (ERA) Congress comes to a close, we’re grateful for the diverse perspectives across the scientific, medical and patient communities helping to shape the future of research and care in rare nephrology. New data and insights reflect continued momentum across the field and reinforce the evolving understanding of rare kidney diseases, as we continue pioneering for the rare disease community.